Andrew Weiss - Actelion President
President
Mr. Andrew C. Weiss was Senior Vice President, Head Investor Relations and Corporationrationrate Communications and Member of the Extended Actelion Executive Committee of Actelion Ltd since May 2014. Prior to joining Actelion he was the team leader for Life Sciences Equity Research and a financial analyst covering SwissEuropean pharmaceutical biotechnology stocks at Bank Vontobel. Before joining Bank Vontobel in 2007, he worked as an analyst for European Pharmaceuticals at Warburg Dillon Read and as an analystfund manager at Julius Baer. He has a MA degree in Business Administration, Monetary Economics, and Corporationrationrate Law from Universitaet Zuerich and is a Chartered Financial Analyst . since 2014.
| Tenure | 10 years |
| Professional Marks | CFA |
| Phone | 41 61 565 65 65 |
| Web | http://www.actelion.com |
Actelion Management Efficiency
The company has return on total asset (ROA) of 23.87 % which means that it generated a profit of $23.87 on every $100 spent on assets. This is very large. Similarly, it shows a return on equity (ROE) of 47.08 %, meaning that it generated $47.08 on every $100 dollars invested by stockholders. Actelion's management efficiency ratios could be used to measure how well Actelion manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Richard Barker | Noble plc | 42 | |
| Sanjaya Sood | Transocean | N/A | |
| Stephen Butz | Noble plc | 46 | |
| Howard Davis | Transocean | 65 | |
| Adam Peakes | Noble plc | 44 | |
| Ewan Andrew | Diageo PLC ADR | N/A | |
| Natasha Hayes | Crimson Wine | 42 | |
| Lori Beaudion | Duckhorn Portfolio | 60 | |
| MarkAnthony Mey | Transocean | 57 | |
| David Cutter | Diageo PLC ADR | 48 | |
| Zachary Rasmuson | Duckhorn Portfolio | 47 | |
| Deirdre Mahlan | Diageo PLC ADR | 56 | |
| Joseph Caporella | National Beverage Corp | 64 | |
| Keelan Adamson | Transocean | 54 | |
| Scott Marks | Noble plc | 58 | |
| Robert Eifler | Noble plc | 44 | |
| Debra Crew | Diageo PLC ADR | 54 | |
| Deepak Munganahalli | Transocean | N/A | |
| John OKeeffe | Diageo PLC ADR | 52 | |
| Brady Long | Transocean | 51 | |
| Mark Monroe | Transocean | 63 | |
Management Performance
| Return On Equity | 47.08 | |||
| Return On Asset | 23.87 |
Actelion UNSP Leadership Team
Elected by the shareholders, the Actelion's board of directors comprises two types of representatives: Actelion inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Actelion. The board's role is to monitor Actelion's management team and ensure that shareholders' interests are well served. Actelion's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Actelion's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Rudi Frank, Senior Vice President Head Global Quality Management, Member of the Extended Executive Committee | ||
| Marian Borovsky, Senior Vice President Group General Counsel, Member of the Extended Executive Committee, Corporate Secretary to the Board of Directors | ||
| Thomas Widman, Co-Founder | ||
| Nicholas Franco, Executive Vice President Chief Business Development Officer, Member of the Executive Committee | ||
| Christian Albrich, Senior Vice President Head Global Human Resources and a member of the Extended Actelion Executive Committee | ||
| Martine Clozel, Senior Vice President Chief Scientific Officer, Head of Drug Discovery, Pharmacology & Preclinical Development, Member of the Extended Executive Committee | ||
| Robert Bertolini, Member of the Board of Directors | ||
| Juhani Anttila, Member of the Board of Directors | ||
| JeanPierre Garnier, Chairman of the Board of Directors | ||
| David Stout, Member of the Board of Directors | ||
| JeanPaul Clozel, CEO, Member of the Executive Committee, Delegate of the Board of Directors | ||
| Guy Braunstein, Executive Vice President Head of Global Clinical Development, Member of the Executive Committee | ||
| Herna Verhagen, Member of the Board of Directors | ||
| Andrew Weiss, Senior Vice President Head Investor Relations and Corporate Communications, Member of the Extended Executive Committee | ||
| Michael Jacobi, Member of the Board of Directors | ||
| Jean Malo, Member of the Board of Directors | ||
| Otto Schwarz, COO, Executive Vice President Member of the Executive Committee | ||
| Andre Muller, CFO, Executive Vice President Member of the Executive Committee | ||
| Peter Gruss, Member of the Board of Directors | ||
| John Greisch, Member of the Board of Directors |
Actelion Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Actelion a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 47.08 | |||
| Return On Asset | 23.87 | |||
| Profit Margin | 28.89 % | |||
| Operating Margin | 33.62 % | |||
| Current Valuation | 28.53 B | |||
| Shares Owned By Institutions | 0.07 % | |||
| Price To Earning | 41.61 X | |||
| Price To Book | 18.03 X | |||
| Price To Sales | 11.87 X | |||
| Revenue | 2.49 B |
Pair Trading with Actelion
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Actelion position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Actelion will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Biogen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biogen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biogen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biogen Inc to buy it.
The correlation of Biogen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biogen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biogen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biogen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Other Consideration for investing in Actelion Pink Sheet
If you are still planning to invest in Actelion UNSP check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Actelion's history and understand the potential risks before investing.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Transaction History View history of all your transactions and understand their impact on performance |